Semaglutide PCD Franchise in India: 2026 Guide for Distributors

Semaglutide Injection Pen PCD Franchise & Distributorship in India — Sematide™ 2 mg/3 ml and 4 mg/3 ml pre-filled pens by Trumac Healthcare

Semaglutide is the fastest-growing molecule in Indian diabetology this year. Since its Indian patent expired in March 2026, approved generic pens have reached chemists at a fraction of the earlier price, and doctors who could not prescribe it to most patients before now do so routinely. For PCD franchise partners, distributors and pharmacy owners, this is a rare opening: a high-value, once-weekly injectable with strong prescription pull and, in most districts, very few local suppliers. This guide explains how the semaglutide PCD franchise works with Trumac Healthcare, what the product is, what you need to start and how to handle a cold-chain product profitably.

View Sematide Semaglutide Injection Pen – product details 📱 WhatsApp for franchise rates

Why semaglutide is a strong PCD opportunity in 2026

• Patent expiry opened the market. Semaglutide’s Indian patent lapsed in March 2026 and generic versions launched within days, followed by price cuts from the originator. Industry reports put the monthly therapy cost at roughly ₹2,000–₹3,500 for generics, against well over ₹10,000 before expiry.
• Demand is rising fast. Reported monthly sales of semaglutide in India rose several-fold within two months of generic entry, and dozens of companies have entered the segment — but distribution outside the metros is still thin.
• Large, chronic patient base. Type 2 diabetes with obesity or cardiovascular risk is common in urban and semi-urban India. A once-weekly injection fits patients who struggle with daily tablets, so repeat prescriptions are steady.
• High ticket size, low counter competition. Each pen is a premium, prescription-driven product. A district monopoly in a specialist-led molecule gives better value per call than another crowded oral antidiabetic.

About Sematide™ – Trumac Healthcare’s semaglutide injection pen

Sematide semaglutide injection is a single-patient-use pre-filled pen for once-weekly subcutaneous injection, supplied in two strengths that together cover the standard titration schedule:

Pen	Concentration	Dose per injection	Carton contents
Sematide 2 mg/3 ml	0.68 mg/ml	0.25 mg or 0.5 mg	1 pre-filled pen, 6 ultra-fine 32G needles, pack insert
Sematide 4 mg/3 ml	1.34 mg/ml	1 mg	1 pre-filled pen, 4 ultra-fine 32G needles, pack insert

The 2 mg pen covers the four-week initiation phase (0.25 mg weekly) and early maintenance (0.5 mg weekly); the 4 mg pen covers 1 mg weekly maintenance. Stocking both strengths lets one chemist or distributor serve a patient through the whole titration, which is what keeps repeat orders coming.

What Trumac Healthcare offers franchise partners and distributors

• Monopoly rights at district or state level for the Sematide range.
• Competitive net rates with healthy PTR/PTS margins, shared on enquiry for your territory and volume.
• Cold-chain dispatch in insulated, ice-packed shippers from our depot to your location.
• Promotional support – visual aids, product literature, patient medication guides and doctor-detailing material.
• Backend support for billing, documentation, batch Certificates of Analysis and replacement handling.
• A complete diabetes basket to sell alongside semaglutide – see the cardiac and diabetic products franchise range, and the oral semaglutide tablet composition.

Who can take a semaglutide franchise

• PCD franchise owners and pharma marketing companies adding a premium diabetology product
• Medical representatives and area managers with diabetologist, endocrinologist and physician contacts
• Distributors and C&F agents with refrigerated storage
• Retail and hospital pharmacies, weight-management and diabetes clinics with a licensed pharmacy

Documents and investment needed

To start a semaglutide PCD franchise you need a valid drug licence (retail or wholesale, Forms 20B/21B or equivalent), GST registration, and a pharmacy refrigerator able to hold 2–8 °C with a daily temperature log. Because the pen is a high-value product, most partners begin with a small opening order of both strengths and scale up once prescriptions are established in their territory; tell us your expected monthly volume and we will suggest an opening quantity.

Handling a cold-chain product the right way

• Store unopened pens at 2–8 °C, away from the freezer compartment; never freeze, and discard any pen that has frozen.
• Keep pens in the outer carton to protect from light.
• Dispense with a cold pack for the patient’s journey home, and explain the in-use rule: after first use a pen may be kept refrigerated or below 30 °C and must be discarded 56 days after first use.
• Check the shipper’s temperature indicator on receipt and report any excursion to us immediately.

Prescribing and compliance notes

Semaglutide is a prescription-only medicine. It is used as an adjunct to diet and exercise for glycaemic control in adults with type 2 diabetes, and to reduce cardiovascular risk in adults with type 2 diabetes and established cardiovascular disease. It is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2, and in pregnancy. Promotion must stay within the approved indications on the product’s label, and sales must be made only against a valid prescription. Full clinical information is on the Sematide product page.

How to start in four steps

1. Send your district or state, drug licence and GST details on WhatsApp at +91 90416 77932.
2. We confirm monopoly availability for your territory and share net rates for both pen strengths.
3. Sign the franchise agreement and place the opening order.
4. Receive cold-chain dispatch with promotional material, and start detailing.

Frequently asked questions